Lung volume reduction using glue composition
View Patent ↗The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.
1. A method of reducing lung volume in a subject comprising:
providing a glue composition comprising a cross-linking moiety of a heat stabilized glutaraldehyde, a pharmaceutically acceptable carrier, an adhering moiety, and a cross-linkable moiety of an albumin, wherein the cross-linkable moiety is covalently linked to the cross-linking moiety, and wherein the adhering moiety is coupled to the cross-linkable moiety and is a member selected from the group consisting of alpha-1 antitrypsin, elafin, and a serpin;
administering an effective amount of said glue composition to a localized region of damaged lung tissue of said subject;
collapsing a first portion or all of the lung of said subject wherein said first portion comprises said localized region of damaged lung tissue;
allowing said adhering moiety to bind to different sites of lung tissue; and
re-inflating a second portion of the lung of said subject wherein said second portion does not comprise said damaged lung tissue, thereby reducing lung volume.
2. The method as recited in claim 1 wherein said lung tissue comprises epithelial lining fluid.
3. The method as recited in claim 1 wherein said different sites of lung tissue are within an enlarged air space.
4. The method as recited in claim 1 wherein said method is performed with prior identification of said damaged lung tissue.
5. The method as recited in claim 1 wherein said method does not damage epithelial cells within lung tissue.
6. The method as recited in claim 1 wherein said method damages epithelial cells within lung tissue by further administering a sclerosing agent.
7. The method as recited in claim 6 wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum , streptokinase, and urokinase.
8. The method as recited in claim 1 wherein said glue composition is less than 10 microns.
9. The method as recited in claim 1 wherein said glue composition is less than 5 microns.
10. The method as recited in claim 1 wherein said glue composition is less than 1 micron.
11. The method as recited in claim 1 wherein said administering is carried out via inhalation.
12. The method as recited in claim 11 wherein said inhalation is carried out via the mouth.
13. The method as recited in claim 1 wherein said administering is carried out via trans-thoracic administration.
14. The method as recited in claim 1 wherein said administering is carried out by placing a bronchoscope in a bronchi of a deep lung region.
15. The method as recited in claim 14 , further comprising placing a catheter through said bronchoscope to reach a subsegmental bronchi.
16. The method as recited in claim 15 wherein said catheter comprises an expandable balloon-like structure.
17. The method as recited in claim 1 , further comprising administering an anti-surfactant.
18. The method as recited in claim 1 wherein said collapsing comprises use of negative pressure from within the lung of said subject.
19. The method as recited in claim 1 wherein said collapsing comprises use of positive pressure from without the lung of said subject.
20. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises sodium glutamate.
21. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises mannitol.
22. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises dextrose.
23. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises cysteine hydrochloride.
24. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises liposomes.
25. The method of claim 1 wherein said albumin is isolated from a mammal.
26. The method of claim 1 wherein said albumin is porcine albumin.
27. The method of claim 1 wherein said albumin is human albumin.
28. The method of claim 1 wherein said albumin is bovine albumin.
29. The method of claim 1 wherein said albumin is recombinant albumin.
30. The method of claim 1 , wherein the adhering moiety is alpha-1 antitrypsin.
31. A method of treating a pulmonary condition comprising:
providing a glue composition comprising a cross-linking moiety of a heat stabilized glutaraldehyde, a cross-linkable moiety of an albumin, and an adhering moiety, wherein the adhering moiety adheres in less than 3 hours, wherein the cross-linkable moiety is covalently linked to the cross-linking moiety, and wherein the adhering moiety is coupled to the cross-linkable moiety and is a member selected from the group consisting of alpha-1 antitrypsin, elafin, and a serpin;
administering an effective amount of said glue composition to a localized region of damaged lung tissue of a subject;
collapsing a first portion or all of the lung of said subject wherein said first portion comprises said localized region of damaged lung tissue;
allowing said adhering moiety to adhere different sites of lung tissue; and
re-inflating a second portion of the lung of said subject wherein said second portion does not comprise said damaged lung tissue, thereby reducing lung volume.
32. The method as recited in claim 31 wherein said lung tissue comprises epithelial lining fluid.
33. The method as recited in claim 31 wherein said pulmonary condition is emphysema.
34. The method as recited in claim 31 wherein said pulmonary condition is chronic obstructive pulmonary disease.
35. A method of treating a damaged lung of a subject, comprising:
administering an effective amount of a glue composition to a localized region of damaged lung tissue of the subject, wherein the glue composition comprises an adhering moiety, albumin and a heat stabilized glutaraldehyde, wherein the albumin is covalently linked to the heat stabilized glutaraldehyde, and wherein the adhering moiety is coupled to albumin and is a member selected from the group consisting of alpha-1 antitrypsin, elafin, and a serpin;
collapsing a first portion or all of the lung of the subject, wherein the first portion comprises the localized region of damaged lung tissue; and
re-inflating a second portion of the lung of the subject, wherein the second portion does not comprise at least a portion of the damaged lung tissue, thereby treating the damaged lung.
36. A method of treating a damaged lung of a subject, comprising:
administering an effective amount of a composition to a localized region of damaged lung tissue of the subject, wherein the composition comprises a first adhering moiety coupled with a first albumin and a second adhering moiety coupled with a second albumin, wherein each of the first and second adhering moieties is a member selected from the group consisting of alpha-1 antitrypsin, elafin, and a serpin;
collapsing a first portion or all of the lung of the subject, wherein the first portion comprises the localized region of damaged lung tissue;
administering an effective amount of a cross-linking activating moiety of a heat stabilized glutaraldehyde to the localized region of damaged lung tissue of the subject, so as to cross-link the first albumin with the second albumin; and
re-inflating a second portion of the lung of the subject, wherein the second portion does not comprise at least a portion of the damaged lung tissue, thereby treating the damaged lung.